OMNIPAQUE Iohexol

Get an overview of OMNIPAQUE (iohexol injection), including its generic name, formulation (i.e. pill, oral solution, injection, inhaled medicine) and why it’s used. The medication in OMNIPAQUE can be sold under different names.

Refer to the “Also Known As” section to reference different products that include the same medication as OMNIPAQUE.

Drug Basics

Brand Name: OMNIPAQUE

Generic Name: IOHEXOL

Drug Type: HUMAN PRESCRIPTION DRUG

Route: INTRAVENOUS

Dosage Form: INJECTION

Data Current As Of: 2018-10-07

indications & usage

intrathecal administration

Adults

OMNIPAQUE 180, 240, and 300

  • Myelography (lumbar, thoracic, cervical, total columnar)
  • Computerized Tomography (CT) (myelography, cisternography, ventriculography)

Pediatrics

OMNIPAQUE 180

  • Myelography (lumbar, thoracic, cervical, total columnar)
  • CT (myelography, cisternography)

intravascular administration

Adults

OMNIPAQUE 140

  • Intra-arterial digital subtraction angiography of the head, neck, abdominal, renal and peripheral vessels.

OMNIPAQUE 240

  • CT head imaging
  • Peripheral venography (phlebography).

OMNIPAQUE 300

  • Aortography including studies of the aortic arch, abdominal aorta and its branches
  • CT head and body imaging
  • Cerebral arteriography
  • Peripheral venography (phlebography)
  • Peripheral arteriography
  • Excretory urography.

OMNIPAQUE 350

  • Angiocardiography (ventriculography, selective coronary arteriography)
  • Aortography including studies of the aortic root, aortic arch, ascending aorta, abdominal aorta and its branches
  • CT head and body imaging
  • Intravenous digital subtraction angiography of the head, neck, abdominal, renal and peripheral vessels
  • Peripheral arteriography
  • Excretory urography.

Pediatrics

OMNIPAQUE 240

  • CT head and body imaging.

OMNIPAQUE 300

  • Angiocardiography (ventriculography)
  • Excretory urography
  • CT head and body imaging.

OMNIPAQUE 350

  • Angiocardiography (ventriculography, pulmonary arteriography, venography, and studies of the collateral arteries)
  • Aortography including the aortic root, aortic arch, ascending and descending aorta.

oral or rectal administration

Adults

OMNIPAQUE 350

  • Oral radiographic examination of the gastrointestinal tract.

Pediatrics

OMNIPAQUE 180, 240 and 300

  • Oral and rectal radiographic examination of the gastrointestinal tract.

oral administration in conjunction with intravenous administration

Diluted OMNIPAQUE Injection

Adults

OMNIPAQUE 240, 300 and 350 diluted and administered orally in conjunction with OMNIPAQUE 300 administered intravenously

  • CT of the abdomen.

Pediatrics

OMNIPAQUE 240, 300 and 350 diluted and administered orally in conjunction with OMNIPAQUE 240 or OMNIPAQUE 300 administered intravenously

  • CT of the abdomen.

OMNIPAQUE Oral Solution

Adults

OMNIPAQUE oral solution 9 and 12 administered orally in conjunction with OMNIPAQUE 300 administered intravenously

  • CT of the abdomen.

Pediatrics

OMNIPAQUE oral solution 9 and 12 administered orally in conjunction with OMNIPAQUE 240 or OMNIPAQUE 300 administered intravenously

  • CT of the abdomen.

intraarticular administration

Adults

OMNIPAQUE 240, 300, and 350

  • Arthrography.

body cavity administration

Adults

OMNIPAQUE 240

  • Endoscopic retrograde pancreatography (ERP) and cholangiopancreatography (ERCP)
  • Herniography
  • Hysterosalpingography.

OMNIPAQUE 300

  • Hysterosalpingography.

Pediatrics

OMNIPAQUE 240, 300 and 350 diluted

  • Voiding cystourethrography (VCU).

patient counseling information

Hypersensitivity Reactions

Advise the patient concerning the risk of hypersensitivity reactions that can occur both during and after OMNIPAQUE administration. Advise the patient to report any signs or symptoms of hypersensitivity reactions during the procedure and to seek immediate medical attention for any signs or symptoms experienced after discharge [see Warnings and Precautions (5.3) ]

Advise patients to inform their physician if they develop a rash after receiving OMNIPAQUE [ see Warnings and Precautions (5.11) ].

Contrast Induced Acute Kidney Injury

Advise the patient concerning appropriate hydration to decrease the risk of contrast induced acute kidney injury [ see Warnings and Precautions (5.4) ].

Extravasation

If extravasation occurs during injection, advise patients to seek medical care for progression of symptoms [ see Warnings and Precautions (5.7) ].

Lactation

Advise a lactating woman that interruption of breastfeeding is not necessary. However, to avoid any exposure, a lactating woman may consider pumping and discarding breast milk for 10 hours after OMNIPAQUE administration [see Use in Specific Populations (8.2)].

Distributed by GE Healthcare Inc., Marlborough, MA 01752 U.S.A.
Manufactured by GE Healthcare Ireland Limited, Cork, Ireland

GE Healthcare

OMNIPAQUE is a trademark of General Electric Company or one of its subsidiaries.
GE and the GE Monogram are trademarks of General Electric Company.
Product of Norwegian origin.

© 2018 General Electric Company - All rights reserved.

ONC-1U-CORK
Revised April 2018

also known as

This drug label information is as submitted to the Food and Drug Administration (FDA) and is intended for informational purposes only. If you think you may have a medical emergency, immediately call your doctor or dial 911. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Search Drugs and Medication

Or Browse by Name